Viracta Therapeutics

About Viracta Therapeutics

Viracta Therapeutics (NASDAQ:VIRX) focuses on advancing innovative treatments for patients battling cancer and viral-associated malignancies. The company is dedicated to developing targeted and precise epigenetic therapies, leveraging its proprietary drug platform to disrupt cancer cells' growth and survival mechanisms. Viracta's key projects aim at addressing the unmet medical needs of individuals suffering from various types of lymphoma and solid tumors, with a particular emphasis on Epstein-Barr virus (EBV)-associated diseases. Their objectives include pushing the boundaries of personalized medicine to improve treatment outcomes and enhance the quality of life for cancer patients.

What is Viracta Therapeutics known for?

Snapshot

1998

Year founded

Employees

California, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Viracta Therapeutics

Nanatinostat, in combination with valganciclovir, targets Epstein-Barr virus (EBV)-associated cancers.
Pipeline extends to treatments for EBV-positive lymphomas, including diffuse large B-cell lymphoma.
Exploring nanatinostat for potential efficacy in other viral-associated malignancies.
Collaboration with leading oncology institutions for the advancement of viral-associated cancer therapies.
Initiating global clinical trials to extend the reach and impact of nanatinostat treatments.
Focused research on developing novel therapeutic approaches for viruses associated with cancer.